Per the reviewed 2017 Inducement Equity Plan, Global Blood Therapeutics Inc (NASDAQ: GBT) committee on January 1, 2019, gave three of its new employees the choice to buy an aggregate of 6,000 shares (common stock category).
The common shares were sold to the new employees for $41.05 per share- the December 31, 2018 closing price.
The Awards are in line with NASDAQ Listing Rule and Company’s Compensation policy
The awards as mentioned above to the new employees were granted given as motivation material and are in line with NASDAQ Listing Rule 5635(c)(4) as it is with the January 2017 plan.
On December 4 the company had announced similar with the one above that the compensation committee had granted six new employees option to buy 29,250 shares of the common stock category for $31.54 (the closing price of the day the grant was issued).
Similarly, the awards were granted as incentives under the NASDAQ Listing Rule 5635(c)(4) and the company’s Amended and Restated 2017 Inducement Equity plan (the Plan).
Svoronos Appointed to the Board of Directors
GBT has been committed to establishing a motivated staff and strong leadership. Mid last month the company appointed Dawn Svoronos to its Board of Directors. Ms. Svoronos joins the board with over 30 years of experience in the biopharmaceutical space. She has worked for about 25 years at the Merck & Co. and is hoped to strengthen the company’s board with her excellent skills and talents.
Speaking about the appointment, GBT’s M.D Ted W. Love said that, “Her extensive commercial expertise will be invaluable as we continue on the trajectory of submitting a New Drug Application for voxelotor for the treatment of sickle cell disease under an accelerated approval pathway and prepare for our first commercial launch.”
The company’s compensation committee operates under NASDAQ’s authority and is comprised of four members; Deval L. Patrick, Mark L. Perry, Scott Morrison, and Wendy L. Yarno. The general role of the committee is to carry out responsibilities relating to the compensation company’s staff including and not limited to the directors and executives. The committee carries out its responsibility on behalf of the board of directors.
In other news, Global Blood Therapeutics presented at the37th Annual J.P. Morgan Healthcare Conference that was attended by more than 9,000 individuals. The entire presentation together with the Q&A session has been posted on the company’s website for replays.